Market news, stock analysis and investing ideas

Inovio Prices $75 Million Stock Offering at $1.05: What It Means for INO

Inovio priced new shares and pre-funded warrants at $1.05, well under Thursday's $1.45 close. The stock opened pre-market 22.41% lower, then closed Friday at $1.22, above the offer price.

Inovio Prices $75 Million Stock Offering at $1.05: What It Means for INO

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced a proposed public stock offering at 4:01 p.m. ET on Nov. 5, after the regular session closed, and priced it at 11:18 p.m. ET: 58,747,235 shares at $1.05 and pre-funded warrants for 12,681,337 shares at $1.05. Gross proceeds, before fees and expenses, are expected to be about $75 million.

A steep discount that Friday's buyers partly reversed

The offer price of $1.05 sits well below Thursday's $1.45 close. Shares opened Friday's pre-market session 22.41% under that close, then recovered part of the loss and closed at $1.22, above the offer price. The dilution (more shares dividing the same company) is large against a micro-cap, and the stock's recent swings make the price path hard to read.

Shares fell on the offering news, then bounced Friday

The selling started before the price was known. After the 4:01 p.m. announcement, shares fell 15.21% in Thursday's after-hours trading (the session after the 4 p.m. close) to $1.23. The terms came in the late-night pricing release.

On Friday in pre-market trading (the session before the 9:30 a.m. open), shares traded at about $1.13, down 8.49% from Thursday's after-hours close and 22.41% from Thursday's close. About 4.95 million shares changed hands, and the pre-market low was $1.08.

In the regular session the stock rose 8.0% from its pre-market close to $1.22, which left it 16.21% below Thursday's close. It traded between $1.07 and $1.27 on 33.61 million shares, or 1.24 times its 10-day average volume. In after-hours trading Friday the stock rose 4.53% to $1.27 on about 389,000 shares.

The path into the deal was volatile. INO closed at $0.6024 on Oct. 30, down 21.95%, then jumped 213.75% to $1.89 on Nov. 2. It slid to $1.66, $1.62 and $1.45 over the next three sessions. From Oct. 8 through Nov. 5 the stock gained 33.03%.

Why the offering weighed on the stock

A stock offering adds shares, so each existing share owns a smaller slice of the company. The deal's size matters here. Inovio has a market value of about $125.63 million and a float (shares available to trade) of about 103.01 million shares. Against that float, the company is selling 58,747,235 shares and warrants for 12,681,337 more.

Each pre-funded warrant costs the share price minus $0.001 and can be exercised immediately for one share at $0.001, according to the final prospectus supplement. The offer price was set below the $1.45 Thursday close, which the filing cites as the last reported sale price.

What the terms and filings show

  • Underwriters: Jefferies and Piper Sandler are joint book-running managers, and H.C. Wainwright & Co. is lead manager.
  • Option: underwriters have 30 days to buy up to 10,714,285 more shares at $1.05, less discounts and commissions.
  • Registration: the shares come from a shelf registration filed July 2 and declared effective July 10.
  • Status: Inovio describes itself as a smaller reporting company, which faces reduced reporting requirements.
  • Earnings: the company filed an 8-K on results of operations at 4:13 p.m. ET on Nov. 5.

Earlier, on Oct. 20, the company announced a favorable judgment in litigation with VGXI, Inc. and GeneOne Life Science.

What comes next

  • The offering is expected to close on or about Nov. 9, subject to customary conditions.
  • The underwriters' option to buy up to 10,714,285 more shares runs for 30 days.
  • No earnings date is on the calendar.

Bottom line

Inovio raised about $75 million at $1.05, a price well under where the stock had traded a day earlier. Shares closed Friday at $1.22 and traded at $1.27 after hours. The new shares and warrants add to a float of about 103.01 million shares.


This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.

This article is for informational purposes only and is not investment advice.

Read the original report